Clinical proteomics: translating benchside promise into bedside reality.
The ultimate goal of proteomics is to characterize the information flow through protein networks. This information can be a cause, or a consequence, of disease processes. Clinical proteomics is an exciting new subdiscipline of proteomics that involves the application of proteomic technologies at the bedside, and cancer, in particular, is a model disease for studying such applications. Here, we describe proteomic technologies that are being developed to detect cancer earlier, to discover the next generation of targets and imaging biomarkers, and finally to tailor the therapy to the patient.
Petricoin
Emanuel F
EF
FDA-NCI Clinical Proteomics Program, Division of Therapeutic Proteins, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA. petricoin@cber.fda.gov
Zoon
Kathryn C
KC
Kohn
Elise C
EC
Barrett
J Carl
JC
Liotta
Lance A
LA
D005260:Female; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D020543:Proteome / Q000737:chemistry / Q000502:physiology; D013678:Technology, Pharmaceutical / Q000639:trends*
D020543:Proteome